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Abstract
Invasive fungal disease (IFD) remains a signiﬁcant cause of mortality in haematology patients. Management strategies range from empiric
therapy to pre-emptive approaches. Prophylaxis with mould-active agents has been evaluated, but the optimal strategy remains unclear.
We present here a retrospective analysis of the pre-emptive strategy implemented at our institution. We analysed 348 consecutive neu-
tropenic episodes in 234 patients. The main elements of our pre-emptive strategy included twice-weekly Galactomannan testing and
weekly computed tomography (CT) scan. Antifungal prophylaxis usually consisted of ﬂuconazole (400 mg once weekly). Antifungal treat-
ment was started if criteria for IFD (including possible) were fulﬁlled. Along with the incidence of antifungal treatment and IFD, we also
analysed the adherence to the strategy. Adherence was good but suboptimal with 81% of CT scans having been performed at an inter-
val of 10 days or less. Concerning antifungal treatment, in 56 episodes the patient was receiving a mould-active agent as secondary pro-
phylaxis. Antifungal treatment was started during 39% of the remaining episodes. In all, 109 cases of IFD were diagnosed, 51 being
probable or proven. Forty-nine patients died before day 100, IFD directly caused or contributed to death in six patients. Two cases of
IFD were diagnosed post-mortem and were missed by our pre-emptive strategy. Our pre-emptive strategy is feasible and safe with an
acceptable rate of IFD and associated mortality, while avoiding anti-fungal treatment in a signiﬁcant proportion of patients. The exact
role of pre-emptive treatment compared with systematic mould-active prophylaxis can only be determined in a well-designed random-
ized trial.
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Introduction
Invasive fungal disease (IFD) is a major cause of morbidity
and mortality in immunocompromised patients. Patients with
haematological malignancies who receive an allogeneic hae-
matopoietic stem cell transplantation or intensive chemo-
therapy are at high risk for developing IFD. Though
prophylaxis with ﬂuconazole has become standard care in
this patient population [1] IFD caused by mould pathogens
as well as breakthrough yeast infections remain a concern.
Over the past decades, various strategies have been
employed in an attempt to reduce the incidence of IFD.
These range from a pre-emptive approach, which focuses on
early detection of IFD, to empiric treatment for patients
with prolonged fever, or general mould-active antifungal pro-
phylaxis for all patients at high risk for IFD.
Although an empiric strategy usually leads to overtreat-
ment [2], pre-emptive strategies harbour the risk of delayed
treatment, which has been associated with poorer outcome
[3,4]. With the emergence of new well-tolerated mould-
active antifungal agents in the past decade, there has been
increasing interest in prophylactic strategies.
Although a reduced incidence of IFD along with a survival
beneﬁt could be shown in randomized trials evaluating prophy-
laxis with posaconazole [5,6], a similar study with voriconazole
showed no beneﬁt [7]. Furthermore, signiﬁcant concerns
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regarding anti-mould prophylaxis remain including fungal resis-
tance, excess toxicity and ﬁnancial aspects. Hence, the optimal
management of IFD in high-risk patients remains unclear.
At our institution, a precisely outlined pre-emptive strat-
egy has been in place for over 5 years. The emerging data
and debate on antifungal prophylaxis have prompted us to
evaluate our pre-emptive approach.
Patients and Methods
Study design and deﬁnitions
We performed a retrospective chart review evaluating our
pre-emptive treatment strategy of IFD in all neutropenic epi-
sodes following myeloablative allogeneic haematopoietic stem
cell transplantation or chemotherapy with an expected neu-
tropenia of at least 7 days at our institution between Sep-
tember 2004 and May 2009. More than one treatment
episode could be analysed per patient. Data were retrieved
from a surveillance database as well as discharge letters and
outpatient records. Computed tomography scans, Galacto-
mannan (GM) results, cultures and histology ﬁndings as well
as autopsy reports were reviewed in original. We evaluated
the adherence to the pre-emptive strategy, the frequency of
treatment with antifungal agents as well as the incidence of
IFD. The analysis was restricted to the ﬁrst 100 days after
transplantation or start of chemotherapy. In the ﬁnal analysis,
IFD was classiﬁed according to the 2008 revised deﬁnitions
[8]. All patients gave written informed consent to the treat-
ment and the analysis of outcome data.
Pre-emptive strategy
Our institutional pre-emptive strategy has been in place since
2004. All patients were subject to surveillance as outlined
below, though the adherence to the strategy was not moni-
tored systematically.
Antifungal prophylaxis consisted of ﬂuconazole 400 mg
once weekly, with the exception of patients with a previous
history of IFD who received secondary prophylaxis with an
adequate antifungal agent, usually voriconazole (Table 1).
Throughout hospitalization, GM assays (Platelia Aspergillus;
BioRad Laboratories, Hercules, CA, USA; cutoff for positiv-
ity: 0.5) were analysed twice weekly, as well as at any other
time at which IFD was suspected. Furthermore, high-resolu-
tion computed tomography (HRCT) of the chest was sug-
gested to be performed at least every 7–10 days during
neutropenia or high-dose steroid treatment, or at any other
time at which signs of infection occurred. In patients with
pulmonary inﬁltrates a bronchoalveolar lavage (BAL) was
advised. From the BAL, direct microscopy and culture were
always performed, while GM (cutoff for positivity: 1.0) was
obtained in select cases before 2008 and systematically
thereafter.
The results of the various screening procedures were
evaluated according to the 2002 IFD deﬁnitions [9] until
2008 and the revised deﬁnitions thereafter [8]. According to
these deﬁnitions, ﬁndings on HRCT that qualiﬁed as a clinical
criterion included halo, air-crescent-sign and cavity in the
2002 deﬁnitions, as well as dense lesions without halo in the
revised criteria. As soon as the criteria for possible, probable
or proven IFD were fulﬁlled, antifungal treatment was initi-
ated. First-line treatment for suspected mould infection con-
sisted of voriconazole, though alternative antifungal
treatment (e.g. posaconazole or liposomal amphotericin B)
could be given in selected cases. First-line treatment for sus-
pected yeast infection consisted of caspofungin. Response
was closely monitored and treatment was modiﬁed in cases
of refractory IFD or excess toxicity.
In patients with neutropenic fever refractory to at least
4 days of broad-spectrum antibiotics and concurrent mucosi-
tis or worsening general condition, but not fulﬁlling the crite-
ria for IFD, caspofungin could be given empirically at the
discretion of the treating physician.
Supportive care
All patients were treated in single rooms equipped with
special high-efﬁciency particle air ﬁlters until recovery of
TABLE 1. Patient characteristics
Characteristic n (%)
Sex
Male 132 (56)
Female 102 (44)
Age, years
Median (range) 48.6 (18–77)
Underlying disease
Acute lymphoblastic leukaemia 40 (17)
Acute myeloid leukaemia 127 (54)
Myelodysplastic syndrome 22 (9)
Lymphoma 21 (9)
Chronic myeloid leukaemia 9 (4)
Myeloproliferative neoplasm 8 (3)
Other 7 (3)
Treatment episodes 348
Myeloablative chemotherapy 173 (50)
Allogeneic transplantation 175 (50)
Antifungal prophylaxis
Fluconazolea 290 (83)
Secondary antifungal prophylaxis 56 (16)
Voriconazole 48
Posaconazole 2
Caspofungin 5
Amphotericin B 1
No prophylaxis 2 (1)
Duration of neutropenia (<500/lL), days
Median 19
Range 6–258
Duration of neutropenia (<100/lL), days
Median 13
Range 1–252
aFluconazole was given at a dose of 400 mg once weekly.
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neutrophils. Bacterial cultures from rectal swabs and screen-
ing cultures for moulds from nasal swabs were performed at
the time of admission. No antibiotic prophylaxis was given.
In the event of fever (>38.5C or >38.0C recorded
twice), blood cultures were collected from the central
venous catheter and peripherally. Patients were examined
for signs of infection and further evaluation was performed
as clinically indicated.
Patients with fever in neutropenia were treated empiri-
cally with a broad-spectrum antibiotic (e.g. cefepime or
tazobactam/piperacillin). Patients were treated as inpatients
until neutrophil recovery and resolution of any severe
complications.
Statistical analysis
The incidence of newly initiated antifungal therapy and IFD
was calculated using the cumulative incidence method with
the risk of death as a competing risk. Incidences were com-
pared using the Gray test.
Results
Patient characteristics
Between September 2004 and May 2009, 348 consecutive
neutropenic treatment episodes were analysed in 234
patients. Patient characteristics are shown in Table 1.
Details of the pre-emptive strategy
We began by assessing the adherence to particular aspects
of the pre-emptive strategy guidelines. Of the surveillance
process, we reviewed the performance of regular HRCT
scans and BAL in the case of inﬁltrates, because we judged
these elements to be essential to the early detection of IFD
along with regular GM testing. Twice weekly GM testing was
included in a standardized blood-draw schedule so did not
need to be prescribed individually; as a consequence, we did
not speciﬁcally analyse the adherence to this point.
The majority of HRCT was performed at the suggested
intervals, with a median time between ﬁrst day of neutrope-
nia and ﬁrst HRCT scan as well as the interval between sub-
sequent scans of 7 days (range 0–49 days), and 81% of
HRCT scans were performed at an interval of 10 days or
less. The median number of HRCT performed per neutrope-
nic episode was three (range 0–14), with two episodes dur-
ing which no HRCT scan was performed. Reasons for this
could not be determined retrospectively, neither of these
two patients developed an IFD. Of the episodes in which a
pulmonary IFD was detected primarily by HRCT, 11 of 83
(13%) were detected in the ﬁrst HRCT scan performed
within the ﬁrst week of admission. In the case of inﬁltrates,
BAL was performed in 53 of 86 episodes (62%).
Treatment with antifungal agents and incidence of IFD
In 56 neutropenic episodes (16%), the patients were already
receiving mould-active antifungals as secondary prophylaxis
(Table 1). Antifungal treatment was initiated during 114 of
292 (39%) remaining episodes. First-line drugs used were
voriconazole (n = 67), caspofungin (n = 28), amphotericin
B/liposomal amphotericin B (n = 15), posaconazole (n = 2),
ﬂuconazole (400 mg/day) (n = 1), or a two-drug combination
(n = 1). Antifungal treatment was started at a median of
13 days (range )13 to 90, negative numbers result from
treatment started before the day of transplant or start of
chemotherapy) after start of chemotherapy or day of trans-
plant. The cumulative incidence of newly initiated antifungal
treatment is shown in Fig. 1. In 93 neutropenic episodes,
antifungal treatment was initiated in the context of a diagno-
sis of at least a possible IFD, while in 21 episodes, treatment
was begun empirically for persisting fever or pulmonary inﬁl-
trates not fulﬁlling the criteria for IFD.
Finally we analysed the incidence of IFD. Overall, 109
cases of IFD were newly diagnosed during 103 neutropenic
episodes (30%) in 100 patients (43%), at a median of 14 days
(range )13 to 89) from start of chemotherapy or day of
transplant (Table 2). Table 2 shows the distribution of IFD
category and pathogens. Fig. 1 shows the cumulative inci-
dence of the occurrence of IFD during a neutropenic epi-
sode, reaching 30% at day 100. The most commonly involved
pathogen was Aspergillus accounting for 31/51 (61%) probable
or proven IFD, followed by Candida. Almost all cases of pro-
ven invasive aspergillosis or zygomycosis involved the lungs,
although one case involved the small intestine. We docu-
mented two cases of proven IFD with Hormographiella asper-
gillata, a rare non-aspergillus mould, with one of these cases
being disseminated, and this patient died as a result of IFD.
Proven IFD caused by Candida species was documented by
blood culture in 11 cases, two cases were disseminated, and
one case was diagnosed post-mortem in the autopsy with
FIG. 1. Cumulative incidence (CI) of newly initiated antifungal treat-
ment and invasive fungal disease (IFD) until day 100.
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Candida emboli in the mesenteric arteries. Of all cases of
IFD, 96 (88%) were diagnosed while the patient was receiv-
ing ﬂuconazole prophylaxis, whereas nine (8%) occurred dur-
ing secondary prophylaxis with a mould-active agent and four
(4%) during therapy for a previously diagnosed IFD in the
same neutropenic episode or empiric antifungal therapy.
Sixty (55%) cases of IFD occurred in the context of chemo-
therapy, the remaining 49 (45%) were related to allogeneic
transplantation, with no statistically signiﬁcant difference in
the cumulative incidence of IFD between the two treatment
modalities (data not shown). Two cases of proven IFD (one
case of pulmonary aspergillosis, one case of candidaemia
mentioned above) were missed by our pre-emptive strategy
and diagnosed at autopsy.
Outcome
Of the 234 patients, 49 (21%) died before day 100 following
56 treatment episodes. Of these, 26 patients had 29 cases of
IFD. Autopsy was performed in 27 patients, of which 15 had
a diagnosis of IFD ante-mortem. Evidence of IFD was present
at autopsy in three of these patients, along with two further
cases of IFD that were diagnosed by autopsy in patients with
no evidence of IFD before death as mentioned above. The
IFD was considered to be the primary cause of death in two
patients, one of which had not been diagnosed ante-mortem,
and to have probably contributed to death in four cases.
Overall, 12% of deaths (6/49) in 3% of the original patient
population (6/234) were attributable to IFD.
Discussion
Here we present a retrospective analysis of our pre-emptive
treatment strategy of IFD in a high-risk patient group. In light
of increasing data on prophylactic strategies with anti-mould
agents, we were interested in evaluating the efﬁcacy of our
strategy with respect to the adherence to the recommended
strategy, the frequency of anti-fungal treatment, and most
importantly the incidence of IFD.
First, we found a good but suboptimal adherence to the
installed guidelines. Almost 20% of HRCT scans were per-
formed at a greater interval than the suggested maximum of
10 days, and in the case of inﬁltrates, BAL was not per-
formed in over one-third of cases. Considering the relatively
long observation period and the large number of physicians
involved, in our view the adherence observed lies in the
expected range in this setting, and stricter adherence is likely
to occur only in the context of a controlled study.
With the application of our strategy, antifungal treatment
was started in 39% of patients who were receiving ﬂuconaz-
ole prophylaxis. A comparison with published data is compli-
cated by the lack of a standardized pre-emptive strategy,
varying criteria triggering antifungal treatment and different
patient populations. Whereas our strategy foresees system-
atic HRCT screening of all patients regardless of whether
signs of infection are present, most studies evaluating pre-
emptive therapy applied a clinically driven diagnostic
approach, i.e. only patients with clinical signs of possible IFD
such as persisting fever, were submitted to a diagnostic eval-
uation. Cordonnier et al. performed a randomized controlled
trial of empirical versus pre-emptive antifungal therapy [10].
In the pre-emptive treatment arm, antifungal therapy was
started after 4 days of fever only in the case of deﬁned clini-
cal signs or positive GM. In the pre-emptive treatment
group, 39% of patients received antifungal treatment versus
61% in the empirical treatment group. The higher incidence
of antifungal treatment in this study compared with our anal-
ysis might be explained by the less stringent criteria trigger-
ing antifungal treatment, which included clinical signs that do
not fulﬁl the deﬁnition of possible IFD. Another study by
Girmenia et al. treated only patients with at least possible
IFD similar to our strategy; however, again, diagnostic evalua-
tion was performed only in the case of persisting fever [11].
Using this approach, antifungals were administered during
22% of all neutropenic episodes, which are further differenti-
ated into risk groups with 39% of high-risk episodes, and 2%
TABLE 2. Invasive fungal disease (IFD) category, involved
pathogens, distribution of treatment type and antifungal
prophylaxis or treatment at the time of diagnosis of IFD
IFD characteristics n (%)
Possible 58 (53)
Pulmonary 52
Other 6
Probable 23 (21)
Aspergillus 23
Proven 28 (26)
Aspergillus 8
A. fumigatus 5
A. nidulans 1
Aspergillus, not speciﬁeda 2
Candida 14
C. albicans 3
C. krusei 4
C. norvegensis 2
Other (C. parapsilosis, C. keﬁr 0
C. dublinensis, C. glabrata) 1
Candida, not speciﬁeda 2
Zygomycetesa 4
Other (Alternaria, Hormographiella aspergillata, Penicillium spp.)
Treatment episode
Chemotherapy 60 (55)
Allogeneic transplantation 49 (45)
Prophylaxis/treatment at diagnosis of IFD
Fluconazole (400 mg once weekly) 96 (88)
Mould-active prophylaxis 9 (8)
Antifungal treatment for previous IFD 2 (2)
Empirical antifungal treatment 2 (2)
aHistological diagnosis (based on morphology), no culture obtained.
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in patients receiving mould-active prophylaxis. Of the few
published reports on pre-emptive therapy, this compares
best with our strategy and the incidence of pre-emptive
therapy is similar. However, major differences include the
prospective controlled setting and patient selection, which
did not include allogeneic transplantation, a treatment entity
associated with a particularly high risk of IFD [12,13]. In a
prospective feasibility study evaluating pre-emptive therapy
by Maertens et al. [14] neutropenic episodes following trans-
plantation as well as chemotherapy were included. Antifungal
treatment was initiated in 14% of treatment episodes, a rela-
tively low incidence that can be explained at least in part by
the stringent criteria applied, which foresaw starting treat-
ment only in patients with positive mycological criteria. In
summary, it seems that our systematic screening strategy
and less stringent treatment triggers can in part explain the
relatively high proportion of episodes in which antifungal
therapy was initiated.
However, the clinically more relevant question concerns
the incidence of IFD occurring with a speciﬁc antifungal strat-
egy. We diagnosed a total of 109 cases of IFD, occurring in
30% of all neutropenic episodes. However, over half of these
were classiﬁed as possible IFD, which is probably explained
by our systematic screening strategy, leaving 51 cases of
probable or proven IFD. Of these, 14 were proven infections
with Candida, which can probably not be explained by our
atypical ﬂuconazole prophylaxis (with once-weekly dosing)
because six cases of proven Candida infection occurred
under therapy for a previous IFD or secondary prophylaxis,
and four further cases were caused by Candida krusei, which
is resistant to ﬂuconazole.
In the randomized study by Cordonnier et al. mentioned
above, probable or proven IFD was diagnosed in 9.1% of
patients [10]. This incidence is slightly lower than our results,
and might be explained in part by the high proportion of
patients included after autologous transplantation, which is
associated with a low risk of IFD [15,16]. The incidence of
IFD reported by Girmenia et al. was 22% including possible,
with 14% of cases being probable or proven, which is in line
with our results [11].
The emerging question will be whether pre-emptive strat-
egies are still justiﬁed in light of new data for systematic
anti-mould prophylaxis. In two large studies evaluating sys-
tematic anti-mould prophylaxis with voriconazole and posa-
conazole, the incidence of probable and proven IFD was 4%
and 5%, respectively [5,7]. This is lower than the incidence
we observed but in both of these studies the incidence of
IFD in the standard ﬂuconazole arm was also fairly low with
8% and 11%, respectively. Furthermore, different patient
populations and follow-up duration additionally complicate a
direct comparison. A valid answer to this question can be
provided only by a well-designed randomized study compar-
ing a pre-emptive and mould-active prophylactic strategy.
Matters of concern in our patient cohort are two unde-
tected cases of IFD diagnosed at autopsy as well as a total of
six deaths caused directly by or associated with IFD. How-
ever, the mortality of 3% attributable to IFD compares well
with data from other pre-emptive and prophylactic strategies
as well as epidemiological data [17]. In the studies by Cor-
donnier and Girmenia mentioned above, 1% and 3% of
patients died of IFD, respectively [10,11], whereas in the
study by Cornely et al. evaluating posaconazole prophylaxis,
3% of the original patient population died as a consequence
of IFD [5]. In addition, it would be unreasonable to expect
that any antifungal strategy might succeed in eliminating IFD-
associated death altogether.
Major drawbacks of our analysis include the retrospective
nature, the heterogeneous patient population, missing data
on toxicity and suboptimal adherence to the guideline. One
might also remark on our differential use of the 2002 IFD
criteria to guide clinical management used during the greater
part of the study period compared with the application of
the 2008 revised criteria for data analysis. As the focus of
our study was the effectiveness of the pre-emptive strategy
in early detection of IFD, this discrepancy should have no
signiﬁcant inﬂuence on the main outcomes and allowed a uni-
form data analysis according to the most recent data.
Despite several drawbacks, we believe that the results
show that this strategy is feasible and safe with an acceptable
rate of IFD and associated mortality, while avoiding anti-fun-
gal treatment in a signiﬁcant proportion of patients, and
offers a reasonable alternative to general prophylaxis even in
a high-risk patient group.
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